Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis.
Autoimmun Rev
; 19(7): 102566, 2020 Jul.
Article
in English
| MEDLINE | ID: covidwho-176093
ABSTRACT
BACKGROUND:
Some disease-modifying agents commonly used to treat patients with rheumatic diseases/autoimmune disorders, such as hydroxychloroquine and colchicine, are under investigation as potential therapies for the "coronavirus disease 2019" (COVID-19). However, the role of such agents as prophylactic tools is still not clear.METHODS:
This is a retrospective study based on a large healthcare computerized database including all patients that were screened for the "Severe Acute Respiratory Syndrome Coronavirus type 2" (SARS-CoV-2) in the study period from February 23rd 2020 to March 31st 2020. A comparison was conducted between subjects tested positive for SARS-CoV-2 and those found negative in terms of rate of administration of hydroxychloroquine/colchicine therapy.RESULTS:
An overall sample of 14,520 subjects were screened for SARS-CoV-2 infection and 1317 resulted positive. No significant difference was found in terms of rates of usage of hydroxychloroquine or colchicine between those who were found positive for SARS-CoV-2 and those who were found negative (0.23% versus 0.25% for hydroxychloroquine, and 0.53% versus 0.48% for colchicine, respectively).CONCLUSION:
These findings raise doubts regarding the protective role of these medications in the battle against SARS-CoV-2 infection.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Colchicine
/
Coronavirus Infections
/
Pandemics
/
Hydroxychloroquine
Type of study:
Observational study
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Asia
Language:
English
Journal:
Autoimmun Rev
Journal subject:
Allergy and Immunology
Year:
2020
Document Type:
Article
Affiliation country:
J.autrev.2020.102566
Similar
MEDLINE
...
LILACS
LIS